Latest treatment of cancer Stories
SUNNYVALE, Calif., March 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC), a clinical stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases, today announced the pricing of a previously announced underwritten registered public offering of 2,200,000 shares of its common stock, representing approximately 3.1% of the shares of common stock currently outstanding, at a...
SAN DIEGO, Calif., Feb. 27, 2013 /PRNewswire/ -- Araxes Pharma LLC announced today it has entered into an exclusive arrangement with Janssen Biotech, Inc. to develop first-in-class therapeutics against a certain target for the treatment of cancer. Araxes Pharma brings together a proven team of early drug developers. The scientific founders are Kevan Shokat, Ph.D., HHMI Investigator and Professor of Molecular and Cellular Pharmacology at UCSF, and Frank McCormick, Ph.D., FRS,...
TSX Venture: QPT EDMONTON, Jan. 22, 2013 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announces that it has achieved 50% accrual having enrolled the 40(th) patient in its ongoing 80 patient Phase II Oregovomab front-line chemo-immunotherapy clinical trial in Italy and the U.S. The objective of this study is to confirm that optimally dosed oregovomab in...
MIAMI, Jan. 18, 2013 /PRNewswire/ -- Biscayne Pharmaceuticals, Inc. today announced that it has closed a $1.5 million financing. The new company is developing novel growth hormone-releasing hormone (GHRH) drugs based on recent discoveries by the company's scientific advisor, Dr. Andrew V. Schally, a world-renowned drug researcher and Nobel laureate who pioneered the field of hypothalamic peptide drugs. Biscayne also announced that it has exclusively licensed intellectual...
SEATTLE, Oct. 3, 2012 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a privately held biopharmaceutical company dedicated to the development of novel Toll-like receptor 8 (TLR8) agonists and antagonists today announced the formation of an exclusive, world-wide collaboration with Celgene Corporation (NASDAQ: CELG) for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer. As part of the strategic agreement, Celgene will retain the exclusive...
SAN DIEGO, Aug 29, 2012 /PRNewswire/ -- Proacta Incorporated announced today that the US Food and Drug Administration has allowed its Investigational New Drug (IND) Application for PR610, a hypoxia-activated, irreversible multi-kinase inhibitor (MKI) for the treatment of cancer. The IND allowance permits Proacta to initiate human clinical trials of this novel, first in class treatment. Initially, development will focus on patients with non-small cell lung cancer who have developed...
SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for the treatment of cancer, announced today that it has entered into a definitive asset purchase agreement with S*BIO Pte Ltd, a privately held biotechnology company, pursuant to which MEI Pharma will acquire S*BIO's exclusive worldwide rights to Pracinostat, an investigational, potential best-in-class, oral histone deacetylase (HDAC)...
LITTLETON, Mass., June 11, 2012 /PRNewswire/ -- Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced today that it has received FDA 510(k) clearance for its MEVION S250 Proton Therapy System. The MEVION S250 is a first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment advantages and capabilities of complex, large, and costly proton therapy systems but with higher patient...
LITTLETON, Mass., March 14, 2012 /PRNewswire/ -- Mevion Medical Systems, a radiation therapy company dedicated to advancing the treatment of cancer, has announced today that it has received CE Marking certification for the MEVION S250 Proton Therapy System. This important commercial milestone indicates that Mevion has completed its development in compliance with the European Union's Medical Device Directive. The CE Marking allows the MEVION S250 to be marketed, sold, and installed in...
SAN DIEGO, Dec. 13, 2011 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced today updated results of a Phase Ib/II trial of the selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor, PCI-32765, for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small...
